Rapport Therapeutics' RAP-219 meets primary endpoint in phase 2 bipolar mania trial
Rapport Therapeutics announced positive phase 2 results for RAP-219, an oral AMPA receptor modulator licensed from Johnson & Johnson, showing improvement in bipolar mania symptoms. This marks the company's second phase 2 success for the asset in 14 months.
